Related Experiment Video

Updated: Apr 5, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

522

BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer

Tu Nguyen-Ngoc1, Hasna Bouchaab, Alex A Adjei

  • 1*Service d'oncologie médicale, Département d'oncologie, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland; and †Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|August 25, 2015
PubMed
Abstract

Insights

Targeting BRAF mutations in non-small-cell lung cancer (NSCLC) shows promise. Combination BRAF and MEK inhibitors demonstrate superior efficacy for V600E BRAF-mutated NSCLC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Non-small-cell lung cancer (NSCLC) is molecularly classified, with actionable targets identified.
  • The RAS-RAF-MEK-ERK pathway is a potential therapeutic target in NSCLC.
  • BRAF mutations are found in 2-4% of NSCLC adenocarcinoma cases.

Purpose of the Study:

  • To review current clinical data on BRAF inhibitors in NSCLC.
  • To evaluate the efficacy of BRAF inhibitor monotherapy and combination therapy.

Main Methods:

  • Review of clinical data on BRAF serine/threonine kinase inhibitors.
  • Evaluation of preliminary data for combination therapy (dabrafenib and trametinib).

Main Results:

  • BRAF inhibitor monotherapy shows encouraging antitumor activity in V600E BRAF-mutated NSCLC.
  • Combination therapy with BRAF and MEK inhibitors is under evaluation.
  • Preliminary data suggest combination therapy is more effective than monotherapy.

Conclusions:

  • Targeting BRAF alterations offers a new therapeutic strategy for a subset of NSCLC.
  • Ongoing prospective trials are refining BRAF inhibitor strategies.
  • Future directions include combining BRAF inhibitors with immunotherapy or ERK inhibitors for enhanced MAPK pathway blockade.

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K